BACKGROUND: A combination of @entity8545 plus an @entity5292 is the most frequently used regimen for febrile episodes in @entity5 @entity1 . However, @entity5292 -related @entity137 occasionally makes this regimen difficult to use as the first-line drug therapy. In the present study, we chose @entity5646 as the alternative to @entity5292 in combination with @entity3400 for @entity221 in @entity4806 @entity1 and we evaluated its effectiveness. METHODS: A total of 31 febrile episodes in 16 @entity1 with @entity5 were evaluted. @entity3400 (200 mg/kg per day) plus @entity5646 (150 mg/kg per day) were administered intravenously following a routine fever work-up. RESULTS: The overall response rate was 67%. The response rate when neutrophil count was less than 100/mm3 was 63%. The side effects were mild and rare. In three @entity1 , all of the microbiologically documented infections were caused by alpha-streptococcus, which required a change in the regimen. CONCLUSIONS: A combination of @entity3400 and @entity5646 provides an effective and non-toxic regimen for first-line therapy in febrile @entity1 with @entity1398 . In contrast, the results of the present study suggest the need for caution with regard to alpha-streptococcus infections.

@entity3400 plus @entity5646 for treatment of XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity5 :: ('MESH:D009369', 'Disease') :: ['neutropenic cancer', 'malignant neoplasms'] @entity4806 :: ('MESH:D063766', 'Disease') :: ['pediatric'] @entity8545 :: ('D047090', 'Chemical') :: ['beta-lactam'] @entity5292 :: ('D000617', 'Chemical') :: ['aminoglycoside'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity3400 :: ('MESH:D010878', 'Chemical') :: ['Piperacillin', 'piperacillin'] @entity221 :: ('MESH:D005334', 'Disease') :: ['neutropenic fever'] @entity5646 :: ('MESH:D001398', 'Chemical') :: ['aztreonam']
@entity221 :: (MESH:D005334,Disease) :: ['neutropenic fever']
